(Q38055656)

27 August 2017

The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia (English)

1 reference

blood coagulation disease

27 August 2017

1 reference

1 reference

E Truelove

1

1 reference

27 August 2017

A K Fielding

series ordinal

2

1 reference

27 August 2017

B J Hunt

series ordinal

3

1 reference

27 August 2017

language of work or name

1 reference

9 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

27

1 reference

27 August 2017

3

1 reference

27 August 2017

553-559

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.290

27 August 2017

0 references

cites work

Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Thrombosis and acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Hypercoagulable state in Cushing's syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Inflammation and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

21 January 2018

Asparaginase revisited

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Peg-asparaginase for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Adverse effects on hemostatic function of drugs used in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Mechanisms of thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Inherited antithrombin deficiency: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Endothelial cell activation. A central pathophysiological process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Effects of Corticosteroids on Coagulation of the Blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Effects of Erwinia-asparaginase on the coagulation system.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Effect of prednisolone on the coagulation and fibrinolytic systems

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Factors with conformational effects on haemostatic serpins: implications in thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Asparaginase decreases clotting factors in vitro: a possible pitfall?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Investigation and management of heritable thrombophilia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

L-asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent carboxylation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Endothelium, venous thromboembolism and ischaemic cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.290

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.290

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference